Published in Oncoimmunology on March 01, 2013
Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res (2014) 1.63
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J (2014) 0.99
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids (2015) 0.85
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol (2016) 0.80
Virus-Based Nanoparticles as Versatile Nanomachines. Annu Rev Virol (2015) 0.78
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Specific carcinoembryonic antigens of the human digestive system. J Exp Med (1965) 9.96
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A (2005) 4.12
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) (2006) 3.74
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 3.01
Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One (2008) 2.90
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Foetal antigens and their role in the diagnosis and clinical management of human neoplasms: a review. Br J Cancer (1972) 2.53
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A (1995) 2.09
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A (2008) 1.90
GM-CSF-based cancer vaccines. Immunol Rev (2002) 1.71
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol (1991) 1.65
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 1.64
Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61
GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine (2007) 1.58
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res (2005) 1.36
Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep (2006) 1.36
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34
Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res (2005) 1.30
Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology (2001) 1.30
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res (2010) 1.28
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Cellular resistance to tumours. Br Med Bull (1967) 1.22
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Embryonic antigen expression in chemically induced rat hepatomas and sarcomas. Int J Cancer (1972) 1.17
Targeting regulatory T cells. Target Oncol (2012) 1.10
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother (2004) 1.09
Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol (2007) 1.08
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 1.03
Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells (2009) 1.03
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
DNA vaccines to attack cancer. Proc Natl Acad Sci U S A (2004) 0.98
Current developments of immunotherapy in the clinic. Curr Opin Immunol (2004) 0.94
Embryonic vaccines against cancer: an early history. Exp Mol Pathol (2009) 0.93
Enhancing cancer vaccines with immunomodulators. Vaccine (2007) 0.87
Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load. Cancer Immunol Immunother (2010) 0.85
Cancer vaccines as a therapeutic strategy. Expert Rev Vaccines (2004) 0.84
Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One (2012) 0.84
Quantitating cellular immune responses to cancer vaccines. Semin Oncol (2003) 0.83
Vaccines for neonatal viral infections: hepatitis B vaccine. Expert Rev Vaccines (2004) 0.79
The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther (2006) 0.79
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
Pro-oxidant and cytotoxic effects of circulating heme. Blood (2002) 2.45
IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 2.24
Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res (2008) 1.78
Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol (2010) 1.75
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A (2002) 1.55
Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal (2007) 1.55
A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res (2008) 1.49
Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol (2010) 1.44
Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem (2007) 1.39
Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem (2003) 1.35
Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic Biol Med (2003) 1.33
Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med (2007) 1.32
Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med (2003) 1.31
Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem (2002) 1.25
Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc Natl Acad Sci U S A (2002) 1.23
Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem (2005) 1.23
Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol (2008) 1.21
The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol (2007) 1.18
Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. Ann N Y Acad Sci (2004) 1.17
Oxygen tolerance and coupling of mitochondrial electron transport. J Biol Chem (2004) 1.17
Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol (2013) 1.15
Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res (2007) 1.14
Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res Health (2010) 1.13
Mitochondrial recycling and aging of cardiac myocytes: the role of autophagocytosis. Exp Gerontol (2003) 1.13
Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res (2010) 1.12
Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem (2003) 1.11
Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem (2002) 1.10
Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog (2010) 1.10
A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J Immunol (2008) 1.09
Mitochondrial metabolism underlies hyperoxic cell damage. Free Radic Biol Med (2004) 1.07
Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans. J Transl Med (2007) 1.05
Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol Nutr Food Res (2005) 1.05
The role of lysosomes in iron metabolism and recycling. Int J Biochem Cell Biol (2011) 1.04
Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol (2009) 1.04
Mitochondrial DNA damage in iron overload. J Biol Chem (2008) 1.04
Generation of oxidants by hypoxic human pulmonary and coronary smooth-muscle cells. Chest (2008) 1.01
D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 1.01
Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials (2012) 0.99
The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through β-catenin-dependent and -independent mechanisms. Mol Cancer Res (2010) 0.99
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia (2007) 0.97
3-Aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem J (2003) 0.95
Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant (2003) 0.95
Cytochrome C oxidase activity and oxygen tolerance. J Biol Chem (2007) 0.94
CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer (2010) 0.93
Embryonic vaccines against cancer: an early history. Exp Mol Pathol (2009) 0.93
Redox activity within the lysosomal compartment: implications for aging and apoptosis. Antioxid Redox Signal (2010) 0.92
Cytocidal effects of atheromatous plaque components: the death zone revisited. FASEB J (2006) 0.91
Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases. Arch Biochem Biophys (2002) 0.91
Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem J (2002) 0.91
Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem (2012) 0.90
The generation of definitive neural stem cells from PiggyBac transposon-induced pluripotent stem cells can be enhanced by induction of the NOTCH signaling pathway. Stem Cells Dev (2012) 0.90
Supression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H(2)S). Free Radic Biol Med (2008) 0.89
Radiation-induced cell death: importance of lysosomal destabilization. Biochem J (2005) 0.89
Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radic Biol Med (2010) 0.89
Globin attenuates the innate immune response to endotoxin. Shock (2002) 0.87
Haem oxygenase-1 overexpression alters intracellular iron distribution. Biochem J (2013) 0.86
Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury. Stem Cells Dev (2015) 0.85
Titanium dioxide (TiO2) nanoparticles preferentially induce cell death in transformed cells in a Bak/Bax-independent fashion. PLoS One (2012) 0.85
Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One (2012) 0.84
Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers. Virol J (2007) 0.82
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Mol Cancer (2012) 0.81
The radioprotective agent, amifostine, suppresses the reactivity of intralysosomal iron. Redox Rep (2003) 0.81
Macrophage migration inhibitory factor manipulation and evaluation in tumoral hypoxic adaptation. Methods Enzymol (2007) 0.81
Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses. Vaccine (2013) 0.80
Natural history of the bruise: formation, elimination, and biological effects of oxidized hemoglobin. Oxid Med Cell Longev (2013) 0.80
Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit. Diagn Microbiol Infect Dis (2011) 0.78
Heritability of erythrocyte sodium permeability: a possible genetic marker for hypertension. Ann Clin Lab Sci (2009) 0.76
Peroxide hormesis? A commentary on "Hydrogen peroxide inhibits caspase-dependent apoptosis by inactivating procaspase-9 in an iron-dependent manner". Free Radic Biol Med (2007) 0.76
A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury. J Clin Psychiatry (2010) 0.75
Bugs, guts, and iron. Shock (2002) 0.75
Cancer research at the James Graham Brown Cancer Center, University of Louisville. Exp Mol Pathol (2009) 0.75
Cytotoxic and mutagenic effects of tobacco-borne free fatty acids. Free Radic Biol Med (2005) 0.75
Our Lilliputian scientific lexicon. Redox Rep (2002) 0.75
Modeling crater formation in femtosecond-pulse laser damage from basic principles. Opt Lett (2015) 0.75